本帖最后由 老马 于 2012-1-13 21:20 编辑 # R& N; B# }% @6 S' F( p
3 f' W5 s4 y- F7 B
爱必妥和阿瓦斯丁的比较
5 A& Y3 ]: N6 B( K* u
$ P- C* B. x8 F8 t5 D, M9 ihttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
$ Y7 k: @7 v" ~* p9 t0 q- E
( ^5 @1 N/ B$ J5 u) Q( C; S
+ M# r {2 e+ q4 o
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/4 ^: ~& M) W8 m$ R% @
==================================================; R9 v: d; s# l. Y; t% m
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* g; K0 y2 K* a% H3 d SPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: i; z% X9 t8 _; T- i, }9 tResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% {# W& |1 A/ _5 _ q* `8 J k: l1 f
|